PCI Biotech develops and commercializes novel therapies for cancer treatment using its photochemical internalization (PCI) technology platform. The PCI technology induces triggered endosomal release, unlocking the potential of therapeutic modalities. The company's lead programs include fimaVACC, which enhances immunotherapy in cancer through triggered endosomal release of antigens, and fimaNAC, which provides intracellular delivery of nucleic acids for emerging nucleic acid therapeutics. PCI Biotech's innovative approach addresses major challenges in the field and has shown promising results in clinical studies.